28 related articles for article (PubMed ID: 38700708)
1. Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder.
Huang Q; Zhong X; Yun Y; Yu B; Huang Y
Neuropsychiatr Dis Treat; 2016; 12():2707-2714. PubMed ID: 27822042
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
4. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
Weihs KL; Murphy W; Abbas R; Chiles D; England RD; Ramaker S; Wajsbrot DB
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):36-46. PubMed ID: 29189044
[TBL] [Abstract][Full Text] [Related]
5. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
[TBL] [Abstract][Full Text] [Related]
6. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.
Radecki DT; Robieson WZ; Gopalkrishnan M; Greenberg E; Aziz M
J Child Adolesc Psychopharmacol; 2024 May; ():. PubMed ID: 38700708
[No Abstract] [Full Text] [Related]
8. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
[TBL] [Abstract][Full Text] [Related]
9. Escitalopram: in the treatment of major depressive disorder in adolescent patients.
Yang LP; Scott LJ
Paediatr Drugs; 2010 Jun; 12(3):155-63. PubMed ID: 20481645
[TBL] [Abstract][Full Text] [Related]
10. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
Bruno A; Morabito P; Spina E; Muscatello MR
Curr Neuropharmacol; 2016; 14(2):191-9. PubMed ID: 26572745
[TBL] [Abstract][Full Text] [Related]
11. Levomilnacipran for the treatment of major depressive disorder: a review.
Asnis GM; Henderson MA
Neuropsychiatr Dis Treat; 2015; 11():125-35. PubMed ID: 25657584
[TBL] [Abstract][Full Text] [Related]
12. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
Scott LJ
CNS Drugs; 2014 Nov; 28(11):1071-82. PubMed ID: 25270036
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]